Mitigating Early Development Risks With The Developick™ Platform

By Heonchang Lim | Director of Formulation Development

The development of biologic drugs is a complex and often lengthy process, fraught with challenges and risks. One of the most critical stages in this journey is the discovery phase, where potential drug candidates are identified and evaluated. Traditional approaches to drug discovery can be time-consuming, resource-intensive, and prone to failure due to inadequate assessment of key attributes.

To address these challenges, Samsung Biologics has developed the DEVELOPICK™ platform. This innovative platform represents a paradigm shift in the early stages of drug development, offering a more efficient and effective way to screen and evaluate biologic candidates. By leveraging advanced analytical methods and minimizing resource consumption, DEVELOPICK™ enables the identification of promising candidates earlier in the process, thereby reducing time-to-market and increasing the likelihood of commercializing safe and effective drug products.

This white paper will delve into the intricacies of the DEVELOPICK™ platform, exploring its key features, benefits, and potential applications. You will learn how this platform can revolutionize the drug discovery process and contribute to the development of novel biologics that have a significant impact on patient health.